Good
Mostly Aligned
Patient Risk:
Low
Summary
Most statements about Cosentyx dosing being driven by indication and treatment phase (initial high-frequency then maintenance) are consistent with the provided label dosing schedules. However, several claims are framed generally as “not adjusted based on disease severity” or as explicitly “not severity-driven,” which is not directly stated in the provided label excerpts, making those parts unsupported.
Category Scores
Accurate Statements
Cosentyx prescribing regimen is based on the specific condition.
Section 2.3 (Plaque Psoriasis dosing), 2.4 (PsA dosing), 2.6 (Ankylosing Spondylitis dosing), 2.8 (nr-axSpA dosing), 2.10 (Hidradenitis Suppurativa dosing).
Cosentyx prescribing regimen is based on the treatment phase (starting dose vs maintenance).
Section 2.3 for Plaque Psoriasis: Weeks 0–4 followed by every 4 weeks thereafter. (Similarly structured schedules appear across other indications in Section 2.)
For Cosentyx, injection frequency is determined by the indication.
Section 2.3 vs 2.4 vs 2.6 vs 2.8 vs 2.10 show differing regimens by indication (e.g., HS includes possibility of increased frequency to every 2 weeks if inadequate response).
For Cosentyx, injection frequency is determined by whether the patient is in the induction (initial) period or ongoing maintenance period.
Section 2.3: Weeks 0–4 then every 4 weeks thereafter; similar “Weeks 0,1,2,3,4 and every 4 weeks thereafter” schedules in Sections 2.10 (HS) and others.
Cosentyx moves from an initial higher-frequency schedule to a less frequent maintenance schedule on a set timeline defined by the indication.
Section 2.3 (Plaque Psoriasis) and Section 2.10 (HS): initial weekly dosing at Weeks 0–4 then maintenance every 4 weeks thereafter (with indication-specific options).
Standard dosing guidance ties injection frequency to indication and treatment phase.
Sections 2.3/2.4/2.6/2.8/2.10 provide indication-specific dosing schedules and include initial (Weeks 0–4) vs maintenance (“every 4 weeks thereafter”) structures.
Cosentyx dosing differs by condition.
Section 2.3 (Plaque Psoriasis) differs from 2.4 (PsA) differs from 2.6 (AS) differs from 2.8 (nr-axSpA) differs from 2.10 (HS).
Unsupported Statements
Cosentyx dosing is not adjusted based on disease severity in the way many biologics are.
The provided label excerpts describe dosing based on indication/phase and some weight-based rules, but do not explicitly address or state that dosing is not adjusted based on disease severity.
Injection frequency does not reflect a severity-driven schedule within a given condition.
The provided excerpts do not explicitly state that within an indication the schedule is not driven by severity; they do describe phase/indication and an HS option for increased frequency if inadequate response.
The standard dosing instructions do not describe dose frequency as depending on severity.
While the provided excerpts show phase/indication and (for HS) “if inadequate response” considerations, they do not explicitly mention “severity” as a factor or explicitly deny severity-based frequency adjustment.
The timeline defined by the indication is a key driver of Cosentyx injection frequency rather than baseline severity.
The label excerpts support that timelines and schedules are set by indication/phase, but they do not address “baseline severity” as a driver or non-driver.
Contradictions
Important Omissions
No explicit evaluation provided for label-supported contraindications, warnings/precautions, drug interactions, or adverse reactions because the user’s claim list focused on dosing frequency/driver. If those were intended, they are not assessed.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claims mainly describe how dosing schedules relate to indication and induction/maintenance phases, which is consistent with label dosing structure. Unsupported framing about “not severity-driven” is unlikely to directly contradict label but is not explicitly substantiated by the provided excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several statements claim dosing is not adjusted based on disease severity, which is not explicitly stated in the provided label excerpts.
Suggested Improvement
Rephrase unsupported parts to reflect what the label excerpts support (indication-specific regimens and an initial Weeks 0–4 period followed by maintenance intervals) without asserting absence of severity-based adjustment unless the label explicitly states that.